argenx SE is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. argenx’s most advanced product candidate, efgartigimod (ARGX-113), is currently in a Phase 3 registrational trial for the treatment of the rare autoimmune disease generalized myasthenia gravis (MG). ARGX-113 is also being developed in three other indications: immune thrombocytopenia (ITP), pemphigus vulgaris (PV) and chronic inflammatory demyelinating polyneuropathy (CIDP). Additionally, argenx is developing its second product candidate, cusatuzumab (ARGX-110), for rare and aggressive hematological cancers, initially for T-cell lymphoma (TCL) and acute myeloid leukemia (AML), as well as high-risk myelodysplastic syndrome (MDS).